98%
921
2 minutes
20
The purpose of this prospective, double-blinded, multirater, systematic replication study was to investigate agreement for aspiration risk, in the same individual, between videofluoroscopic swallow studies (VFSS) and the Yale Swallow Protocol. Participants were 25 consecutive adults referred for dysphagia testing who met the inclusion criteria of completion of a brief cognitive assessment, oral mechanism examination, and no tracheotomy tube. First, all participants were administered the Yale Swallow Protocol by two experienced speech-language pathologists trained in protocol administration. Failure criteria were inability to drink the entire amount, interrupted drinking, or coughing during or immediately after drinking. Second, all participants completed a VFSS within 5-10 min of protocol administration. A speech-language pathologist, blinded to protocol results, reviewed the VFSS to determine aspiration status in a binary (yes/no) manner. Inter-rater agreement between two speech-language pathologists was 100 % for identification of aspiration risk with the Yale Swallow Protocol. Inter-rater agreement between the speech-language pathologist and the radiologist for identification of aspiration status with VFSS was 100 %. Twenty percent of VFSS recordings were viewed again 3-6 months after initial data collection, and intrarater agreement for identification of thin liquid aspiration was 100 %. Sensitivity for the Yale Swallow Protocol = 100 %, specificity = 64 %, positive predictive value = 78 %, and negative predictive value = 100 %. Importantly, all participants who passed the protocol did not aspirate during VFSS. Multiple, double-blinded raters and VFSS as the reference standard agreed with previous research with a single, nonblinded rater and FEES as the reference standard for identification of aspiration risk. The clinical usefulness and validity of the Yale Swallow Protocol for determining aspiration risk in a small sample size of male participants has been confirmed. Future research is needed with a larger and more heterogeneous population sample.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1007/s00455-013-9488-3 | DOI Listing |
Laryngoscope
August 2025
Department of Otolaryngology-Head and Neck Surgery, University of California, San Diego, La Jolla, California, USA.
Objectives: A clinical swallow evaluation (CSE) is a subjective exam with limited diagnostic accuracy. We hypothesize that audiometric data collected superficially can enhance the detection of swallowing dysfunction. This study examines audiometric differences between normal and dysfunctional swallows on Flexible Endoscopic Evaluation of Swallowing (FEES) using a digital stethoscope.
View Article and Find Full Text PDFJAAD Case Rep
August 2025
Department of Dermatology, Yale School of Medicine, New Haven, Connecticut.
Folia Phoniatr Logop
July 2025
Ondokuz Mayıs University Faculty of Health Sciences Department of Speech and Language Therapy, Samsun, Turkey.
Introduction: Systemic amyloidosis, a rare disorder characterized by protein accumulation, affects various organs and can impair swallowing, leading to complications like aspiration pneumonia. This study aimed to measure swallowing function in patients with systemic amyloidosis using both objective and subjective methods of assessment to determine the specific stages and severity of dysphagia.
Methods: Twenty-six patients with amyloidosis underwent a prospective evaluation using Flexible Endoscopic Evaluation of Swallowing (FEES) and the Eating Assessment Tool (EAT-10).
Mult Scler Relat Disord
September 2025
Department of Neurology, Ondokuz Mayıs University School of Medicine, Samsun, Turkey. Electronic address:
Introduction: This study aimed to investigate the ability of the Dysphagia in Multiple Sclerosis Questionnaire (DYMUS) and the Eating Assessment Tool-10 (EAT-10) to detect pharyngeal residue, penetration, and aspiration in individuals with Multiple Sclerosis (IwMS).
Methods: Between March 2024 and January 2025, 108 IwMS were included in the evaluation. Participants first completed the DYMUS and EAT-10.
Therap Adv Gastroenterol
June 2025
Takeda Pharmaceuticals USA, Inc., Lexington, MA, USA.
Background: Eosinophilic esophagitis (EoE) disease severity is not typically reported in clinical practice.
Objectives: To assess real-world EoE disease severity (assessed by physicians and using an adapted Index of Severity for EoE (I-SEE)), physician/patient characteristics, healthcare resource utilization (HCRU), and treatment patterns among adolescents and adults with EoE in the USA.
Design: A noninterventional, retrospective, physician-reported medical chart review.